
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BIOV | CSE | CAD | Delayed | |
BVAXF | OTC Markets | USD | Delayed | |
5LB | Frankfurt | EUR | Delayed |
BioVaxys Technology Corp., a clinical-stage biotechnology company, engages in developing viral and oncology vaccine platforms and immuno-diagnostics. The company offers DPX immune educating technology platform and HapTenix neoantigen tumor cell construct platform for treating cancers, infectious diseases, antigen desensitization, and other immune diseases. It also provides Maveropepimut-S (MVP-S), which has completed phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum resistant ovarian cancer; MVP-S +1 Keytruda that is in IIb clinical trial to treat lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations; BVX-0918, a haptenized tumor cell vaccine for ovarian cancer; and DPX SurMAGE, a formulation of the tumor-associated antigens survivin and MAGE A9 as a dual targeted immunotherapy. In addition, the company develops DPX-RSV that is in phase II clinical stage for Respiratory Syncytial Virus; DPX-Flu, which is in phase I clinical stage used to treat multiple strains of influenza; DPX-Neo, which is in phase I trial used for evaluating UConn Health’s proprietary neoepitopes; DPX-E7 to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue and evaluate the safety in HLA-A2positive patients; and DPX-rPA anthrax vaccine. Further, the company operates HapTenix Platform, a vaccine platform based on the established immunological concept that modifies surface proteins with haptens and T-Cell Antigen Discovery Program. It has agreement with AP Visionaries, Inc. to develop a proprietary DPX formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatening risk of certain food allergies triggered by exposure to peanut/tree nuts or eggs. BioVaxys Technology Corp. is headquartered in Etobicoke, Canada.
Name | Age | Since | Title |
---|---|---|---|
Charles J. Dunton | - | 2021 | Member of Advisory Board |
Yvelise Barrios | - | 2021 | Scientific Adviser |
Kartik Chandran | - | 2021 | Member of Scientific Advisory Board |
James Christopher Passin | 53 | 2016 | Co-Founder, CEO, & Director |
Shmuel Farhi | - | 2021 | Member of Scientific Advisory Board |
Adam Coutts | - | 2021 | Member of Advisory Board |
Anthony John Guy Dutton | 68 | 2022 | Independent Director |
Craig William Loverock | 53 | 2022 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review